BiotechTube
HeartBeam

HeartBeam

Santa Clara, United States· Est.
heartbeam.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $35M

Overview

HeartBeam is pioneering portable cardiac diagnostics with its proprietary technology platform that captures 3D heart electrical signals and synthesizes them into a 12-lead ECG. Founded in 2015 and based in Santa Clara, CA, the company targets the significant unmet need for convenient, medical-grade remote monitoring to accelerate cardiac care upon symptom onset. While its core software for 12-lead synthesis is not yet FDA-cleared for sale in the U.S., HeartBeam is building a waitlist and positions its technology as a platform with future applications in wearables and AI-driven analytics.

Cardiovascular

Technology Platform

Proprietary technology using a portable device to capture 3D heart electrical signals and synthesize them into a 12-lead ECG via a personalized transformation matrix. Platform is protected by >20 patents and is designed for extension into wearables, patches, and AI analytics.

Funding History

3
Total raised:$35M
IPO$15M
Series B$12M
Series A$8M

Opportunities

HeartBeam addresses a large gap in remote cardiac care by aiming to provide medical-grade, comprehensive ECG data outside clinical settings.
The growing telehealth and remote patient monitoring markets, coupled with an aging population and focus on early intervention, present a significant tailwind.
Its platform technology allows for potential expansion into continuous monitoring and integration with other wearable form factors.

Risk Factors

The company's core 12-lead synthesis software is not yet FDA-cleared, creating significant regulatory and timing risk.
It must prove clinical equivalence to the standard 12-lead ECG and successfully commercialize in a competitive landscape against both traditional devices and advancing consumer wearables.
As a pre-revenue public company, it faces ongoing capital needs and execution risk.

Competitive Landscape

HeartBeam competes in the remote cardiac monitoring space against single-lead consumer devices (e.g., Apple Watch, KardiaMobile) and traditional Holter monitors or event recorders. Its key differentiator is the claim of synthesized 12-lead capability. Potential competitors include other companies developing patch-based or portable multi-lead ECGs, as well as large medtech firms with resources to develop similar integrated solutions.

More companies in Diagnostics & Precision Medicine →More companies in United States →